Data for: A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer

Published: 31-03-2020| Version 1 | DOI: 10.17632/yj4byrkjmj.1
Contributor:
Ignace Vergote

Description

Protocol and SAP

Files